000136413 001__ 136413
000136413 005__ 20240321220050.0
000136413 0247_ $$2doi$$a10.3233/JAD-2011-110857
000136413 0247_ $$2pmid$$apmid:21971403
000136413 0247_ $$2ISSN$$a1387-2877
000136413 0247_ $$2ISSN$$a1875-8908
000136413 0247_ $$2altmetric$$aaltmetric:397886
000136413 037__ $$aDZNE-2020-02735
000136413 041__ $$aEnglish
000136413 082__ $$a610
000136413 1001_ $$0P:(DE-HGF)0$$aLewczuk, Piotr$$b0
000136413 245__ $$aCerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease.
000136413 260__ $$aAmsterdam$$bIOS Press$$c2012
000136413 264_1 $$2Crossref$$3print$$bIOS Press$$c2012-01-12
000136413 3367_ $$2DRIVER$$aarticle
000136413 3367_ $$2DataCite$$aOutput Types/Journal article
000136413 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710946247_2064
000136413 3367_ $$2BibTeX$$aARTICLE
000136413 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136413 3367_ $$00$$2EndNote$$aJournal Article
000136413 520__ $$aIn this report, we confirm our previous findings of increased concentrations of soluble amyloid-β protein precursor (sAβPP) in cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) in a large cohort of patients (n = 314), not overlapping with those of our previous study, and we extend our observations by including a control group of participants with normal cognition. In addition, we investigate the effects of age, the APOEε4 genotype, and the blood-CSF barrier function on the concentrations of sAβPPα and sAβPPβ. The study participants were categorized according to clinical-neuropsychological criteria, supported by CSF neurochemical dementia diagnostics (NDD) analyses. sAβPPα concentrations in the AD group (132.0 ± 44.8) were significantly higher than in the control group (105.3 ± 37.3, p < 0.0005) but did not differ from the MCI-AD group (138.5 ± 39.5, p = 0.91). The MCI-AD group differed significantly from the MCI-O (97.3 ± 34.3, p < 0.05) group. There was no difference between the control and the MCI-O groups (p = 0.94). Similarly, sAβPPβ concentrations in the AD group (160.2 ± 54.3) were significantly higher than in the control group (129.9 ± 44.6, p < 0.005) but did not differ from the MCI-AD group (184.0 ± 56.4, p = 0.20). The MCI-AD group differed significantly from the MCI-O (127.8 ± 46.2, p < 0.05) group. There was no difference between the control and the MCI-O groups (p > 0.99). We observed highly significant correlation of the two sAβPP forms. Age and the CSF-serum albumin ratio were significant albeit weak predictors of the sAβPPα and sAβPPβ concentrations, while carrying the APOEε4 allele did not influenced the levels of the sAβPP forms. Taken together, the results strongly suggest that CSF sAβPP concentrations may be considered as an extension of already available NDD tools.
000136413 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000136413 588__ $$aDataset connected to CrossRef, PubMed,
000136413 650_7 $$2NLM Chemicals$$aAmyloid beta-Protein Precursor
000136413 650_7 $$2NLM Chemicals$$aApolipoprotein E4
000136413 650_7 $$2NLM Chemicals$$aBiomarkers
000136413 650_2 $$2MeSH$$aAdult
000136413 650_2 $$2MeSH$$aAged
000136413 650_2 $$2MeSH$$aAged, 80 and over
000136413 650_2 $$2MeSH$$aAlzheimer Disease: cerebrospinal fluid
000136413 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000136413 650_2 $$2MeSH$$aAmyloid beta-Protein Precursor: cerebrospinal fluid
000136413 650_2 $$2MeSH$$aApolipoprotein E4: genetics
000136413 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000136413 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000136413 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000136413 650_2 $$2MeSH$$aCohort Studies
000136413 650_2 $$2MeSH$$aFemale
000136413 650_2 $$2MeSH$$aHumans
000136413 650_2 $$2MeSH$$aMale
000136413 650_2 $$2MeSH$$aMiddle Aged
000136413 7001_ $$0P:(DE-HGF)0$$aPopp, Julius$$b1
000136413 7001_ $$0P:(DE-HGF)0$$aLelental, Natalia$$b2
000136413 7001_ $$0P:(DE-HGF)0$$aKölsch, Heike$$b3
000136413 7001_ $$0P:(DE-2719)2000015$$aMaier, Wolfgang$$b4$$udzne
000136413 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b5$$eLast author$$udzne
000136413 7001_ $$0P:(DE-HGF)0$$aKornhuber, Johannes$$b6
000136413 77318 $$2Crossref$$3journal-article$$a10.3233/jad-2011-110857$$b : IOS Press, 2012-01-12$$n1$$p119-125$$tJournal of Alzheimer's Disease$$v28$$x1875-8908$$y2012
000136413 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-2011-110857$$gVol. 28, no. 1, p. 119 - 125$$n1$$p119-125$$q28:1<119 - 125$$tJournal of Alzheimer's disease$$v28$$x1875-8908$$y2012
000136413 8564_ $$uhttps://pub.dzne.de/record/136413/files/DZNE-2020-02735_Restricted.pdf
000136413 8564_ $$uhttps://pub.dzne.de/record/136413/files/DZNE-2020-02735_Restricted.pdf?subformat=pdfa$$xpdfa
000136413 909CO $$ooai:pub.dzne.de:136413$$pVDB
000136413 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000015$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000136413 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000136413 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000136413 9141_ $$y2012
000136413 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2017
000136413 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136413 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136413 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136413 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136413 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136413 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000136413 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136413 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136413 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136413 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136413 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136413 9201_ $$0I:(DE-2719)7000001$$kU Clinical Researchers - Bonn$$lU Clinical Researchers - Bonn$$x0
000136413 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x1
000136413 980__ $$ajournal
000136413 980__ $$aVDB
000136413 980__ $$aI:(DE-2719)7000001
000136413 980__ $$aI:(DE-2719)1011102
000136413 980__ $$aUNRESTRICTED